Navigation Links
U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims
Date:1/23/2008

NEW YORK, Jan. 23 /PRNewswire-USNewswire/ -- The Public Patent Foundation ("PUBPAT") announced today that the U.S. Patent & Trademark Office has rejected four key HIV/AIDS drug patents held by Gilead Sciences that relate to the drug known generically as tenofovir disoproxil fumarate (TDF), a key weapon in the battle against HIV/AIDS. Gilead markets TDF in the United States under the brand name VIREAD and as a part of its ATRIPLA combination product.

Roughly 40 million people worldwide are infected with HIV/AIDS, including more than 1.2 million Americans. The U.S. Food and Drug Administration will not allow anyone other than Gilead distribute TDF in the United States because Gilead claims the four patents challenged by PUBPAT and now rejected by the Patent Office give them the exclusive right to do so.

"Every person suffering from HIV/AIDS has a right to get the best medical treatment science can offer, without any unjustified impediments placed in their way," said Dan Ravicher, PUBPAT's Executive Director. "This includes Americans infected with HIV/AIDS, who are entitled to the best pharmaceuticals possible without undeserved patents making them exorbitantly expensive."

In its filings challenging the patents, PUBPAT submitted prior art that Gilead had not disclosed to the Patent Office during the patent application process that resulted in the patents being granted to the Foster City, California, biopharmaceutical giant. PUBPAT also described in detail how the prior art would have prohibited the patents from being issued in the first place, had the Patent Office had been aware of it. The Patent Office has now agreed with PUBPAT and found that each of the four Gilead Sciences patents are undeserved. Although Gilead has the right to respond to the Patent Office's rejections of the patents, third party requests for re-examination, like the ones filed by PUBPAT against the four Gilead TDF patents, are successful in causing the reviewed patents to either be revoked or changed more than two-thirds of the time.

"We are extremely pleased that the Patent Office has agreed with us that Gilead's TDF patents are invalid," said Ravicher. "This means that we are now well on the way towards ending the harm being caused to the public by Gilead's use of the patents to prevent anyone else from offering TDF to HIV/AIDS patients in the United States."

The Gilead Sciences TDF patents challenged by PUBPAT that have now been rejected by the Patent Office are U.S. Patents No. 5,922,695, 5,935,946, 5,977,089 and 6,043,230. Gilead has applied for similar patents on TDF in other countries throughout the world, including India, where they have received fierce opposition by non-profit AIDS patient groups.

More information about the reexaminations of the four Gilead Sciences TDF patents challenged by PUBPAT, including copies of the official Office Actions issued by the Patent Office rejecting all of the claims of each of the four patents, can be found at http://www.pubpat.org/gileadhivaidsdrug.htm.
Contact:

Daniel Ravicher, Executive Director

Public Patent Foundation

(212) 796-0570

info@pubpat.org

http://www.pubpat.org

About the Public Patent Foundation

The Public Patent Foundation ("PUBPAT") is a not-for-profit legal services organization working to protect the public from the harms caused by the patent system, particularly the harms caused by undeserved patents and unsound patent policy. PUBPAT provides the general public and those specific persons or businesses otherwise deprived of access to the system governing patents, with representation, advocacy, and education.


'/>"/>
SOURCE Public Patent Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
2. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
3. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
4. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
7. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
8. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
9. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
10. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
11. Dog Law Officers Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey ... Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes you. ... of my mind for years, but actually doing it might have been a while in ...
(Date:1/19/2017)... ... ... the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians are ... who participate in APMs are paid for the quality of care they give to ... a system that delivers better care and one in which clinicians work together to ...
(Date:1/19/2017)... ... 2017 , ... With the cold weather here, many people will have to clear snow with ... large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... for the proper use of snow blowers:, , When removing wet ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
Breaking Medicine News(10 mins):